Carter Van Waes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck
    Clint T Allen
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 10 Center Drive, CRC 4 2732, Bethesda, Maryland 20892, USA
    Head Neck 29:959-71. 2007
  2. ncbi request reprint Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma
    Clint Allen
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3182-90. 2007
  3. pmc Targeting NF-κB in mouse models of lung adenocarcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Discov 1:200-2. 2011
  4. ncbi request reprint Head and neck squamous cell carcinoma in patients with Fanconi anemia
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892 1462, USA
    Arch Otolaryngol Head Neck Surg 131:640-1. 2005
  5. ncbi request reprint Nuclear factor-kappaB in development, prevention, and therapy of cancer
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:1076-82. 2007
  6. ncbi request reprint Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:4956-9. 2007
  7. ncbi request reprint Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 63:1400-12. 2005
  8. doi request reprint A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas
    Tin Lap Lee
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892 1419, USA
    Int J Cancer 122:1987-98. 2008
  9. pmc Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute of Deafness and Communication Disorders, National Institutes of Health, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 77:447-54. 2010
  10. pmc CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules
    Matthew S Brown
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 1419, USA
    Clin Cancer Res 16:2295-307. 2010

Detail Information

Publications57

  1. ncbi request reprint Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck
    Clint T Allen
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 10 Center Drive, CRC 4 2732, Bethesda, Maryland 20892, USA
    Head Neck 29:959-71. 2007
    ..Understanding the molecular alterations leading to aberrant NF-kappaB activation in HNSCC may direct investigators to novel therapeutic targets...
  2. ncbi request reprint Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma
    Clint Allen
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3182-90. 2007
    ..Longitudinal changes in these serum factors could be early biomarkers of treatment response and survival...
  3. pmc Targeting NF-κB in mouse models of lung adenocarcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Discov 1:200-2. 2011
    ..Xue et al. demonstrate response and increased survival but development of acquired resistance to proteasome and inhibitor-κB kinase inhibitors targeting NF-κB activation in adenocarcinomas of Kras-activated, p53-deficient mice...
  4. ncbi request reprint Head and neck squamous cell carcinoma in patients with Fanconi anemia
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892 1462, USA
    Arch Otolaryngol Head Neck Surg 131:640-1. 2005
  5. ncbi request reprint Nuclear factor-kappaB in development, prevention, and therapy of cancer
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:1076-82. 2007
    ..Newer agents targeting the proteasome, inhibitor-kappaB kinase, and other upstream kinases involved in NF-kappaB activation have shown anticancer activity in clinical or preclinical studies...
  6. ncbi request reprint Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:4956-9. 2007
  7. ncbi request reprint Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 63:1400-12. 2005
    ....
  8. doi request reprint A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas
    Tin Lap Lee
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892 1419, USA
    Int J Cancer 122:1987-98. 2008
    ..Inhibition of signal activation of both NF-kappaB and STAT3 together with reexpression of p53 could be the most effective strategy to restore BAX/BCL-XL regulation and for cytotoxic therapy of HNSCC...
  9. pmc Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute of Deafness and Communication Disorders, National Institutes of Health, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 77:447-54. 2010
    ....
  10. pmc CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules
    Matthew S Brown
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 1419, USA
    Clin Cancer Res 16:2295-307. 2010
    ....
  11. pmc TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer
    Hai Lu
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA
    Cancer Res 71:6867-77. 2011
    ....
  12. pmc ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation
    Xinping Yang
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 71:3688-700. 2011
    ..Our study reveals ΔNp63 as a master transcription factor that, in coordination with NF-κB/Rels, orchestrates a broad gene program promoting epidermal hyperplasia, inflammation, and the malignant phenotype of HNSCC...
  13. pmc Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms
    Zhong Chen
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, 10 5D55, MSC 1419, Bethesda, MD 20892 1419, USA
    Mol Cancer Ther 7:1949-60. 2008
    ..These findings revealed molecular mechanisms of bortezomib sensitivity and resistance, which are under development as biomarkers for clinical trials in patients with HNSCC...
  14. doi request reprint Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer
    Francisco G Pernas
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:2361-72. 2009
    ..To investigate the underlying molecular mechanism, the proteomic signatures and responses of EGFR and downstream signals have been studied in a panel of HNSCC cell lines and tumor specimens pre- and post-gefitinib treatment...
  15. ncbi request reprint A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status
    Tin Lap Lee
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 1419, USA
    Clin Cancer Res 13:5680-91. 2007
    ....
  16. ncbi request reprint Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma
    Brian Worden
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 1419, USA
    Cancer Res 65:7071-80. 2005
    ....
  17. ncbi request reprint cDNA microarray and bioinformatic analysis of nuclear factor-kappaB related genes in squamous cell carcinoma
    Zhong Chen
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 383:81-99. 2007
    ....
  18. pmc Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer
    Pattatheyil Arun
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 0001, USA
    Clin Cancer Res 15:5974-84. 2009
    ..Here, we investigated the prevalence and function of p65-Ser276 phosphorylation by protein kinase A (PKA) in the malignant phenotype and gene transactivation, and studied p65-Ser276 as a potential target for therapy...
  19. doi request reprint Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer
    Clint Allen
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 14:4175-85. 2008
    ..However, limited clinical activity of bortezomib has been observed in many epithelial malignancies, suggesting this could result from incomplete inhibition of NF-kappaB/RELs or other prosurvival signal pathways...
  20. pmc Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer
    Jonah Cohen
    Howard Hughes Medical Institute NIH Research Scholars Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA
    Cancer Res 69:3415-24. 2009
    ..Together, these findings elucidate a regulatory framework in which attenuated TGFbeta signaling promotes NF-kappaB activation and squamous epithelial malignancy in the setting of altered TP53 status...
  21. ncbi request reprint Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer
    Jay Friedman
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Cancer Res 13:6568-78. 2007
    ....
  22. ncbi request reprint Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101
    Jianming Duan
    National Institute on Deafness and Other Communication Disorders, NIH, CRC Building 10, Room 4 2732, 10 Center Drive, Bethesda, MD 20892, USA
    Mol Cancer Ther 6:37-50. 2007
    ..The combination of HDI and proteasome inhibitor produced increased antitumor activity. Low starting dosages for clinical studies combining HDIs with proteasome inhibitors and IV fluid support may be warranted...
  23. pmc Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status
    Bin Yan
    Head and Neck Surgery Branch, NIDCD, National Institutes of Health, Bethesda, MD 20892, USA
    Genome Biol 9:R53. 2008
    ..However, how NF-kappaB acts as a key regulatory node to modulate global gene expression, and contributes to the malignant heterogeneity of head and neck cancer, is not well understood...
  24. pmc The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth
    Kathryn E King
    Division of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Cancer Res 68:5122-31. 2008
    ..This is the first report indicating that high levels of DeltaNp63alpha interact with activated c-Rel in keratinocytes and SCC, thereby promoting uncontrolled proliferation, a key alteration in the pathogenesis of cancers...
  25. doi request reprint High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers
    Hadley Sharp
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Am J Clin Oncol 31:557-60. 2008
    ....
  26. ncbi request reprint Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine
    Takashi Hirano
    Vaccine Research Section, National Institute on Deafness and Other Communication Disorders, Rockville, MD, USA
    Immunol Lett 107:131-9. 2006
    ..These kinetic antibody patterns and cellular responses may provide useful information regarding to effective mucosal vaccines against NTHi infections...
  27. ncbi request reprint A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma
    Colleen H Druzgal
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bldg 10 CRC, Rm 4 2732, 10 Center Drive, Bethesda, MD 20892, USA
    Head Neck 27:771-84. 2005
    ..Pretreatment and posttreatment serum levels of cytokines and angiogenesis factors were evaluated as markers for outcome in patients with HNSCC...
  28. pmc Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells
    Myong Hee Sung
    Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Room B602, Bldg 41, 41 Library Dr, Bethesda, MD 20892, USA
    Mol Pharmacol 74:1215-22. 2008
    ....
  29. pmc Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells
    Ming Yu
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Res 66:6722-31. 2006
    ....
  30. ncbi request reprint Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas
    Tin Lap Lee
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, 10 5D55, MSC 1419, Bethesda, MD 20892 1419, USA
    Mol Cancer Ther 5:8-19. 2006
    ..Identifying the potential factors and the regulatory pathways in STAT3 activation has important implications for the development and selection of molecularly targeted therapy in HNSCC...
  31. pmc PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer
    Amanda Herzog
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:3808-19. 2013
    ..However, little is known about how these alterations affect response to PI3K/mTOR-targeted agents...
  32. pmc Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma
    Bin Yan
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Center Drive, Bethesda, Maryland 20892, USA
    Genome Biol 8:R78. 2007
    ..However, the molecular expression signatures and transcriptional regulatory controls that underlie the heterogeneity in HNSCCs are not well defined...
  33. ncbi request reprint 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma
    Justin L Ricker
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:8665-73. 2004
    ..To our knowledge, this is the first study to evaluate the effects of 2ME2 in head and neck squamous cell carcinoma...
  34. pmc HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma
    Jay A Friedman
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD
    Transl Oncol 6:429-41. 2013
    ..Our data support investigation of SNX5422/2112 in combination with paclitaxel, cisplatin, and radiotherapy in HNSCC with different TP53 status. ..
  35. pmc Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction
    Bruce J Baum
    Molecular Physiology and Therapeutics Branch, and Neurobiology and Pain Therapeutics Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:19403-7. 2012
    ..AdhAQP1 vector delivery to a single parotid gland was safe and transfer of the hAQP1 cDNA increased parotid flow and relieved symptoms in a subset of subjects...
  36. pmc Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib
    Jason A Poff
    Diagnostic Radiology Department, Clinical Center and Head and Neck Surgery Branch, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Radiology 248:485-91. 2008
    ..To investigate whether combining pulsed high-intensity focused ultrasound (HIFU) with the chemotherapeutic drug bortezomib could improve antitumor activity against murine squamous cell carcinoma (SCC) tumors...
  37. pmc Current and potential inflammation targeted therapies in head and neck cancer
    Frederick Wang
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, 1 Cloister Ct, Bethesda, MD 20814, USA
    Curr Opin Pharmacol 9:389-95. 2009
    ..This review provides an update on recent advances in the understanding of the mechanisms driving cancer-related inflammation in HNSCC and on molecular targeted therapies under preclinical and clinical investigation...
  38. pmc Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer
    Deborah Citrin
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 74:1040-6. 2009
    ..To report the long-term outcomes and toxicity of a regimen of infusion paclitaxel delivered concurrently with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck...
  39. ncbi request reprint Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma
    Angela A Chang
    National Institutes of Health Clinical Research Training Program, National Institute on Deafness and Other Communication Disorders, Bethesda, MD 20892, USA
    Adv Otorhinolaryngol 62:92-102. 2005
    ..Because of its important role, activation of nuclear factor-KappaB by the proteasome and other signal molecules may provide targets for molecular therapy of squamous cell carcinoma and other cancers...
  40. doi request reprint Epidermal overexpression of transgenic ΔNp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF-κB activation
    Jihui Du
    Clinical Genomics Unit and Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, 20892, USA Central Laboratory, Nanshan Hospital, Guangdong Medical College, Shenzhen, Guangdong, 518052, China
    J Pathol 232:356-68. 2014
    ..Published 2013. This article is a U.S. Government work and is in the public domain in the USA. ..
  41. pmc NF-kappaB in carcinoma therapy and prevention
    Matthew Brown
    National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD 20892, USA
    Expert Opin Ther Targets 12:1109-22. 2008
    ..NF-kappaB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas...
  42. ncbi request reprint Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
    Amy Loercher
    Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, Rockville, Maryland 20832 0001, USA
    Cancer Res 64:6511-23. 2004
    ..These results provide evidence that NF-kappaB is an important modulator of gene expression programs that contribute to the malignant phenotype of SCC...
  43. pmc EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
    Christian Freudlsperger
    National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Head and Neck Surgery Branch, Bethesda, MD 20892, USA
    Expert Opin Ther Targets 15:63-74. 2011
    ..This pathway plays a central role in numerous cellular processes including metabolism, cell growth, apoptosis, survival and differentiation, which ultimately contributes to HNSCC progression...
  44. ncbi request reprint Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines
    Caren C Bancroft
    Tumor Biology Section, Head and Neck Surgery Branch, The National Institute on Deafness and Other Communication Disorders, The National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 99:538-48. 2002
    ..We conclude that antagonists of EGFR, PI3K and MEK signal pathways have inhibitory activity against EGFR-induced NF-kappaB and AP-1 activation, IL-8 and VEGF expression and growth by HNSCC. Published 2002 Wiley-Liss, Inc...
  45. pmc Dyskeratosis congenita: the first NIH clinical research workshop
    Sharon A Savage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892, USA
    Pediatr Blood Cancer 53:520-3. 2009
    ..dcoutreach.com/). Ongoing, open collaboration between the clinical, scientific, and family communities is required for continued improvement in our understanding of DC and the clinical consequences of telomeric defects...
  46. ncbi request reprint Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Department of Pathology and Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 10:1565-73. 2004
    ..This trial evaluated if a topically delivered oral rinse containing ketorolac was as safe as and more effective than oral rinse alone in reducing the area of oral leukoplakia...
  47. ncbi request reprint Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor
    Gang Dong
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 10 5D55, MSC 1419, Bethesda, MD 20892 1419, USA
    Oncogene 23:6199-208. 2004
    ....
  48. ncbi request reprint Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer
    Erik S Kass
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland 20892 1750, USA
    Cancer Res 62:5049-57. 2002
    ..These results suggest that CEA may be considered as a possible target for specific vaccine-mediated immunotherapy against HNCs...
  49. pmc The biology of tobacco and nicotine: bench to bedside
    Phillip A Dennis
    Cancer Therapeutics Branch, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20889, USA
    Cancer Epidemiol Biomarkers Prev 14:764-7. 2005
    ..Importantly, new opportunities to use molecular biology to identify and abrogate tobacco-mediated carcinogenesis and to identify high-risk individuals were recognized...
  50. ncbi request reprint Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae
    Xin Xing Gu
    National Institute on Deafness and Other Communication Disorders, 5 Research Court, Rockville, MD 20850, USA
    Vaccine 21:2107-14. 2003
    ..The LOS-TT conjugate is well tolerant in adults and a Phase II evaluation of the conjugate in children is planned...
  51. pmc Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers
    Reza Ehsanian
    Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA
    Cell Commun Signal 9:13. 2011
    ..In particular, quinacrine's role on the NF-κB, p53, and AKT pathways are summarized...
  52. ncbi request reprint Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction
    Bruce J Baum
    Gene Therapy and Therapeutics Branch, Bethesda, MD 20892 1190, USA
    Biochim Biophys Acta 1758:1071-7. 2006
    ..Based on these results, we are developing a clinical trial to test if the hAQP1 cDNA transfer strategy will be clinically effective in restoring salivary flow in patients with IR-induced parotid hypofunction...
  53. doi request reprint Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy
    Jun Wang
    Department of Otolaryngology, University of Pittsburgh Medical School, Pittsburgh, PA, USA
    J Natl Cancer Inst 100:502-12. 2008
    ..Constitutive prosurvival signaling by the phosphoinositide-3 kinase/Akt pathway has been observed in SCCHN cells independent of epidermal growth factor receptor (EGFR) signaling...
  54. ncbi request reprint Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma
    Giovana R Thomas
    Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Papanicolau Building, 1550 NW 10th Avenue, Room 214, Miami, FL 33136, USA
    Cancer Immunol Immunother 53:33-40. 2004
    ..These data provide evidence for a novel mechanism of cytokine-mediated down-modulation of CD80 during malignant progression of HNSCC that can be restored by IFN-gamma...
  55. ncbi request reprint Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer
    Jian Dong
    Department of Cell Biology, Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, Ohio 45267 0521, USA
    Cancer Gene Ther 10:96-104. 2003
    ..Furthermore, the combination of local Flt3-L and HSVTK production, together with GCV administration, does not enhance the distant bystander effect produced by Flt3-L alone...
  56. ncbi request reprint Assessment of gene expression in head and neck carcinoma using laser capture microdissection and real-time reverse transcription polymerase chain reaction
    Pramit S Malhotra
    Department of Otolaryngology Head and Neck Surgery, University of Minnesota Hospitals, Minneapolis, Minnesota, USA
    Laryngoscope 114:2123-8. 2004
    ..To quantify gene expression in tumor cells from human head and neck squamous cell carcinomas (HNSCC) using laser capture microdissection (LCM)...
  57. doi request reprint Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice
    Qing Shuo Zhang
    Oregon Stem Cell Center, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Res 68:1601-8. 2008
    ..The reduction in oxidative DNA damage in tempol-treated FA fibroblasts and mice suggests that its tumor-delaying function may be attributed to its antioxidant activity...